Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + regorafenib
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cadonilimab + regorafenib is a combination therapy being investigated for various cancer indications. Cadonilimab is a tetravalent bispecific antibody that simultaneously targets PD-1 and CTLA-4 immune checkpoints. It was designed with eliminated Fc receptor binding and effector function to improve efficacy and safety. Regorafenib is a multi-kinase inhibitor with antiangiogenic properties. The combination aims to enhance anti-tumor activity by combining immune checkpoint inhibition with antiangiogenesis, particularly in microsatellite stable (MSS) cancers where immune checkpoint inhibitors alone have shown limited efficacy.
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PDGFRA (Platelet-derived growth factor receptor alpha)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on cadonilimab + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + regorafenib.